+

WO2018125851A1 - Systèmes et procédés pour isoler et développer des cellules souches à partir d'urine - Google Patents

Systèmes et procédés pour isoler et développer des cellules souches à partir d'urine Download PDF

Info

Publication number
WO2018125851A1
WO2018125851A1 PCT/US2017/068380 US2017068380W WO2018125851A1 WO 2018125851 A1 WO2018125851 A1 WO 2018125851A1 US 2017068380 W US2017068380 W US 2017068380W WO 2018125851 A1 WO2018125851 A1 WO 2018125851A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
urine
stem cells
therapeutic
urine sample
Prior art date
Application number
PCT/US2017/068380
Other languages
English (en)
Inventor
Michael Moeller
Original Assignee
Michael Moeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Moeller filed Critical Michael Moeller
Publication of WO2018125851A1 publication Critical patent/WO2018125851A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Definitions

  • the invention is directed systems and methods to isolate stem cells from urine. BACKGROUND OF THE INVENTION
  • MSCs Mesenchymal stem cells
  • the invention is directed to a process to isolate stem cells from urine.
  • the invention is directed to a method for collection, processing and therapeutic use of stem cells.
  • the invention is directed to a business method for the collection, transport and use of urine derived mesenchymal stem cells.
  • Fig 1A is a diagram of the renal system
  • Fig IB illustrates stem cell originating site in the kidney.
  • the invention is directed to a process to isolate stem cells from urine.
  • the process includes the steps as provided in steps 1-9.
  • Urine is centrifuged at 500-550g for 10 minutes to pellet all cells
  • Cell culture growth medium is replaced the following day with fresh culture growth medium supplemented with K ⁇ g/ml Gentamicin sulfate; thereafter, growth medium is replaced every 2-3 days
  • the process requires that 1) the urine samples are obtained by non-invasive methods 2) is limited to animal-free cell culture growth medium and 3) does not include bovine based serum. As the process uses animal free serum most regulatory concerns are avoided in addition to a further reduction of cost.
  • the ability to obtain urine naturally or collection via an implemented catheter avoids the necessity to the cells by intrusive methods such as surgical or extraction by suction. Further, having the ability to obtain the cells by non-invasive methods substantially reduces costs and trauma to the patient.
  • the cells derived from this process would be characterized by flow-based immunophenotyping against multiple positive and negative antigenic markers as well as differentiation assays to demonstrate the classic multipotency seen in MSCs. These cells would then be expanded under optimal culture conditions in an animal-free medium to provide commercialized production and application of urine-derived MSCs for various therapies, most specifically, autologous therapies within days or a couple of weeks of obtaining a sample.
  • the process would not require isolation of MSCs from an encapsulating tissue matrix, digestive enzymes, or any of the things that the FDA regards as exceeding "minimal manipulation".
  • UDMSCs urine-derived mesenchymal stem cells
  • the invention is directed to a method for collection, processing and therapeutic use of stem cells including the steps of: a. obtaining a urine sample from a patient;
  • the urine sample is obtained by a non-invasive method and uses only animal free serum.
  • the expanded cells are stored at ambient temperatures. It is appreciated within the scope of the present invention, that it would be possible to provide therapeutic uses of stem cells which are obtained from a patient for use in another patient. However, those skilled in the art will appreciate the benefits of autologuous use.
  • the invention is directed to a business method for the collection, transport and use of urine derived mesenchymal stem cells.
  • Appendix A provides illustration and explanation regarding the process and characterization of the isolated stem cells and, in addition, the related steps regarding commercialization aspects for use of the cells.
  • the business method includes the steps of: a. establishing a physician network with patients interested in therapeutic stem cell uses;
  • processing the urine sample to isolate stem cells contained in the sample h. expanding the cells in a growth medium; and providing a therapeutic amount of the expanded cells as required to the patient from which the urine sample was obtained.
  • MSCs derived from bone marrow, umbilical cord, placenta, and adipose tissue generally illustrate expression of the cell surface markers CD73, CD90, and CD105
  • cells derived from urine illustrate very low or absent expression of CD73 and no detectable expression of CD105. These cells may illustrate positive or negative expression of CD90, suggesting that two cellular populations may be present.
  • MSCs derived from bone marrow, umbilical cord, placenta, and adipose tissue are capable of differentiating into adipocytes, chondrocytes, and osteocytes
  • UDMSCs near the end of their lifespans appear to differentiate into an epithelial-like phenotype with broad, flattened cells.
  • UDMSCs are likely derived by shedding from kidney tubules suggesting that they have potential therapeutic application in kidney repair.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des procédés et des systèmes de collecte et de distribution de matériau d'échantillon biologique obtenu à partir d'urine humaine.
PCT/US2017/068380 2016-12-26 2017-12-24 Systèmes et procédés pour isoler et développer des cellules souches à partir d'urine WO2018125851A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662439106P 2016-12-26 2016-12-26
US62/439,106 2016-12-26

Publications (1)

Publication Number Publication Date
WO2018125851A1 true WO2018125851A1 (fr) 2018-07-05

Family

ID=62710062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/068380 WO2018125851A1 (fr) 2016-12-26 2017-12-24 Systèmes et procédés pour isoler et développer des cellules souches à partir d'urine

Country Status (1)

Country Link
WO (1) WO2018125851A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021031884A1 (fr) * 2019-08-20 2021-02-25 苏州吉美瑞生医学科技有限公司 Procédé de culture de cellules souches rénales dérivées de l'urine et son utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070036767A1 (en) * 2003-06-27 2007-02-15 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
WO2010065239A1 (fr) * 2008-12-05 2010-06-10 Wake Forest University Health Sciences Cellules souches provenant d’urine et leurs procédés d’utilisation
US20140248621A1 (en) * 2012-01-10 2014-09-04 John Collins Microfluidic devices and methods for cell sorting, cell culture and cells based diagnostics and therapeutics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070036767A1 (en) * 2003-06-27 2007-02-15 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
WO2010065239A1 (fr) * 2008-12-05 2010-06-10 Wake Forest University Health Sciences Cellules souches provenant d’urine et leurs procédés d’utilisation
US20140248621A1 (en) * 2012-01-10 2014-09-04 John Collins Microfluidic devices and methods for cell sorting, cell culture and cells based diagnostics and therapeutics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LITTLE, M.: "SBMB Showcase on Research: Generating Kidney Tissue from Pluripotent Stem Cells", AUSTRALIAN BIOCHEMIST, vol. 2, no. 1, 18 July 2016 (2016-07-18), pages 13, XP055607244 *
MORAES, DA ET AL.: "A Reduction in CD 90 (THY-1) Expression Results in Increased Differentiation of Mesenchymal Stromal Cells", STEM CELL RESEARCH & THERAPY, vol. 7, no. 97, 28 July 2016 (2016-07-28), XP055404902 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021031884A1 (fr) * 2019-08-20 2021-02-25 苏州吉美瑞生医学科技有限公司 Procédé de culture de cellules souches rénales dérivées de l'urine et son utilisation

Similar Documents

Publication Publication Date Title
US7547546B2 (en) Progenitor cells from wharton's jelly of human umbilical cord
Araña et al. Adipose tissue-derived mesenchymal stem cells: isolation, expansion, and characterization
Zhu et al. Manual isolation of adipose-derived stem cells from human lipoaspirates
CN103966162B (zh) 一种经血来源间充质干细胞分离方法
EP3523421B1 (fr) Procédé d'isolement de cellules souches mésenchymateuses à partir d'une membrane amniotique de cordon ombilical à l'aide d'un milieu de culture cellulaire
Raposio et al. A standardized method of isolating adipose-derived stem cells for clinical applications
US10329533B2 (en) Regenerative cell and adipose-derived stem cell processing system and method
CN113249317A (zh) 一种人脐带间充质干细胞的分离培养扩增方法及系统
Raposio et al. Isolation of autologous adipose tissue-derived mesenchymal stem cells for bone repair
Pozzobon et al. Isolation of c-Kit+ human amniotic fluid stem cells from second trimester
CN105238749A (zh) 一种复苏骨髓间充质干细胞的方法
CN105238750A (zh) 一种复苏脐带间充质干细胞的方法
CN108685948A (zh) 一种新型医用细胞修复剂的制备方法
CN106754637A (zh) 一种经血源性子宫内膜干细胞的分离提取方法
CN103305461B (zh) 一种以月经产物制备间充质干细胞的方法
CN112553155A (zh) 一种脐带血间充质干细胞培养方法
CN107267453A (zh) 一种用于培养脂肪间充质干细胞的培养基及其应用
Sharifiaghdas et al. Isolation of human adult stem cells from muscle biopsy for future treatment of urinary incontinence
CN105850979A (zh) 一种骨髓间充质干细胞的冻存保护液及冻存方法
WO2021098025A1 (fr) Procédé d'activation in vitro de cellules souches adipeuses pour les transformer en proto-chondrocytes
CN109576216A (zh) 尿来源间充质干细胞的提取及扩增培养方法
WO2018125851A1 (fr) Systèmes et procédés pour isoler et développer des cellules souches à partir d'urine
CN106701671A (zh) 一种利于间充质干细胞应用于骨再生的培养体系
CN106434546B (zh) 完全利用脐带资源制备间充质干细胞的方法
Li et al. Isolation of murine adipose-derived stromal/stem cells using an explant culture method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17888216

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09/10/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17888216

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载